Drug
Chf5993 Pmdi With Hfa 152a
Chf5993 Pmdi With Hfa 152a: highest development phase Phase 2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF5993 pMDI with HFA-152a NCT07301736 | Phase 2 | Asthma |
Latest
No recent events.
Follow Chf5993 Pmdi With Hfa 152a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.